Forma Therapeutics' Olutasidenib Achieves 33% Remission Rate In Acute Myeloid Leukemia Patients

Forma Therapeutics Holdings Inc FMTX announced interim data from its Phase 2 trial of olutasidenib in relapsed/refractory acute myeloid leukemia (R/R AML).
The data will be presented at the upcoming 2021 American Society of Clinical Oncology Annual Meeting.
Olutasidenib demonstrated a 33.3% composite complete remission rate (CR/CRh) in R/R AML patients with the IDH1 mutation.
The CR rate was 30% (37/123) and the CR with partial hematologic recovery (CRh) rate was 3% (4/123).
The duration of the response of 13.8 months is the longest reported in this treatment setting to date.
The median overall survival (OS) was 10.5 months. The median OS for non-CR/CRh responders was 15.0 months.
Among those with CR/CRh, the estimated 18-month survival is 87%; median overall survival has not yet been reached.
A favorable tolerability profile was observed following continuous oral treatment with olutasidenib 150mg twice daily.
Price Action: FMTX shares are up 2.2% at $28.42 during the market session on the last check Thursday.